On August 29th, 2024, Doma’s second bispecific ADC asset, DM005, officially received IND clearance from U.S. FDA and about to begin global phase Ⅰ trial.

On July 4th, 2024, Doma and its affiliate, Xadcera, officially received IND clearance from U.S. FDA for their first bispecific ADC asset, DM001. Prior to that, Doma also officially obtained CTN approval from Australia on Jun 26th, which indicates DM001 global phase Ⅰ trial is coming.

On January 29, 2024, Beijing Time, Doma announced the appointment of Dr. Jun Song as the company's chief strategy officer. Dr. Song assumes the role of leading Doma's strategic and product line planning and the expansion of international collaborations for the company's pipelines.

Doma Biopharmaceutical is dedicated to becoming China's "Flagship" and fostering a "fully integrated life science innovation and incubation platform". This platform seamlessly integrates talent, technology, industry expertise, and capital to nurture exceptional innovative technology companies and make substantial contributions to the sustainable development of healthcare sector, and human well-being.